A80.2 Acute paralytic poliomyelitis, wild virus, indigenous

Name of the Condition

• Acute paralytic poliomyelitis, wild virus, indigenous (ICD-10 Code: A80.2)

Summary

Acute paralytic poliomyelitis, wild virus, indigenous is a severe neurological condition caused by the wild poliovirus, acquired within the patient’s local or national environment. It involves the destruction of motor neurons, leading to muscle weakness or paralysis. The condition is characterized by sudden onset of neurological symptoms, often following a prodromal phase of fever and gastrointestinal illness. While rare in regions with high vaccination coverage, indigenous cases indicate ongoing local transmission risks.

Causes

Acute paralytic poliomyelitis, wild virus, indigenous is caused by the wild poliovirus, a highly infectious enterovirus. The virus spreads via the fecal-oral route, often through contaminated water or food, and can also be transmitted through respiratory droplets. In indigenous cases, the virus circulates within the patient’s community or region, infecting unvaccinated or under-vaccinated individuals.

Risk Factors

• Lack of vaccination or incomplete immunization against polio.
• Living in regions with low vaccination coverage or poor sanitation.
• Poor hygiene practices, increasing exposure to the virus.
• Age, with children under 5 years being most susceptible.

Symptoms

• Sudden onset of muscle weakness or paralysis.
• Asymmetric limb involvement.
• Fever, headache, or stiff neck (common in wild-type polio).
• Difficulty breathing or swallowing (if respiratory muscles are affected).
• Gastrointestinal symptoms (e.g., nausea, vomiting) preceding neurological signs.

Diagnosis

Diagnosis is based on clinical presentation, especially in endemic areas. Laboratory confirmation involves detecting the poliovirus in stool, throat swabs, or cerebrospinal fluid (CSF) via culture or PCR. CSF analysis may show pleocytosis and elevated protein levels. Serological testing for poliovirus antibodies can support diagnosis, though it is less specific for acute infection.

Treatment Options

Treatment focuses on supportive care, as no cure exists for the paralysis. Measures include:

• Pain management and physical therapy to preserve muscle function.
• Respiratory support (e.g., mechanical ventilation) if breathing is impaired.
• Orthopedic interventions (e.g., braces, surgery) for long-term mobility issues.
• Antibiotics for secondary bacterial infections (e.g., urinary tract infections).

Prognosis and Follow-Up

Prognosis varies: some patients recover partially or fully, while others experience permanent paralysis. Follow-up includes regular assessments of motor function, respiratory status, and orthopedic needs. Long-term care may involve rehabilitation, assistive devices, and monitoring for post-polio syndrome (a late complication).

Complications

• Permanent paralysis or muscle atrophy.
• Respiratory failure requiring long-term ventilation.
• Post-polio syndrome (progressive weakness decades after initial infection).
• Secondary infections (e.g., pneumonia, urinary tract infections).

Lifestyle & Prevention

• Complete vaccination with the inactivated poliovirus vaccine (IPV) or oral poliovirus vaccine (OPV) as recommended.
• Improved sanitation and hygiene to reduce fecal-oral transmission.
• Avoiding contact with infected individuals or contaminated water in endemic areas.
• Public health surveillance and outbreak response in high-risk regions.

When to Seek Professional Help

Seek immediate medical attention if you or a child experiences:

• Sudden muscle weakness or paralysis.
• Difficulty breathing or swallowing.
• High fever with neurological symptoms (e.g., stiff neck, headache).
• Recent travel to or residence in a region with known polio transmission.

Tips for Medical Coders

Document the indigenous nature of the wild poliovirus infection, as this distinguishes it from imported cases. Include details on vaccination status, exposure history, and laboratory confirmation (e.g., virus detection in specimens) to support code assignment. Ensure clinical documentation aligns with the specific criteria for A80.2, emphasizing local transmission.